文献速递肾移植

补体激活型抗HLA抗体在肾移植中的基因表达特征与治疗反应

Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment.
PubMed 文献 · J Am Soc Nephrol · 2017-10-17

该前瞻性研究筛查931例肾移植受者,发现补体激活型供者特异性抗体(DSA)与特定的组织分子排斥表型相关,特征为毛细血管补体沉积、NK细胞和单核/巨噬细胞积聚及五个基因表达升高。在116例独立受者中,依库珠单抗较标准治疗显著降低补体激活型DSA患者的3个月排斥发生率(56% vs 19%,P=0.001),但对非补体激活型DSA患者无显著影响。

要点

  • 补体激活型DSA与特定组织分子排斥表型相关。
  • 依库珠单抗可消除该表型并降低早期排斥发生率。
  • 非补体激活型DSA患者未从依库珠单抗获益。

核心结论

  • 循环补体激活型抗HLA DSA与特定的组织分子肾移植排斥表型相关,补体抑制可消除该表型。

研究设计与样本

  • 前瞻性筛查931例肾移植受者,采用组织病理学、免疫染色和移植物基因表达评估排斥表型。
  • 体外人类细胞培养评估效应细胞。

主要发现

  • 补体激活型DSA相关的排斥表型特征为毛细血管补体沉积、NK细胞和单核/巨噬细胞积聚。
  • 五个生物学相关基因(CXCL11、CCL4、MS4A7、MS4A6A、FCGR3A)表达升高,提示内皮活化、IFNγ反应、CD16介导的NK细胞活化和单核/巨噬细胞活化。
  • 依库珠单抗较标准治疗显著降低补体激活型DSA患者的3个月排斥发生率(56%;95%CI 38%至74% vs 19%;95%CI 8%至35%;P=0.001)。
  • 非补体激活型DSA患者中,依库珠单抗与标准治疗的排斥发生率无显著差异(9%;95%CI 2%至25% vs 13%;95%CI 2%至40%;P=0.65)。

临床怎么用

  • 对补体激活型DSA肾移植受者,可考虑依库珠单抗预防排斥。
  • 非补体激活型DSA患者未显示依库珠单抗获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Complement-activating anti-HLA donor-specific antibodies (DSAs) are associated with impaired kidney transplant outcome; however, whether these antibodies induce a specific rejection phenotype and influence response to therapy remains undetermined. We prospectively screened 931 kidney recipients for complement-activating DSAs and used histopathology, immunostaining, and allograft gene expression to assess rejection phenotypes. Effector cells were evaluated using in vitro human cell cultures. Additionally, we assessed the effect of complement inhibition on kidney allograft rejection phenotype and the clinical response to complement inhibition in 116 independent kidney recipients with DSAs at transplant receiving rejection prophylaxis with eculizumab or standard of care (plasma exchange and intravenous Ig) at ten international centers. The histomolecular rejection phenotype associated with complement-activating DSA was characterized by complement deposition and accumulation of natural killer cells and monocytes/macrophages in capillaries and increased expression of five biologically relevant genes (CXCL11, CCL4, MS4A7, MS4A6A, and FCGR3A) indicative of endothelial activation, IFNγ response, CD16-mediated natural killer cell activation, and monocyte/macrophage activation. Compared with standard of care, eculizumab specifically abrogated this histomolecular rejection phenotype and associated with a decreased 3-month rejection incidence rate in patients with complement-activating DSAs (56%; 95% confidence interval [95% CI], 38% to 74% versus 19%; 95% CI, 8% to 35%; P=0.001) but not in those with noncomplement-activating DSAs (9%; 95% CI, 2% to 25% versus 13%; 95% CI, 2% to 40%; P=0.65). In conclusion, circulating complement-activating anti-HLA DSAs are associated with a specific histomolecular kidney allograft rejection phenotype that can be abrogated by complement inhibition.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Lefaucheur C, Viglietti D, Hidalgo LG, et al. Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment. J Am Soc Nephrol. 2017. PMID: 29042454. doi:10.1681/ASN.2017050589

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。